PAVmed, Inc.
(NASDAQ : PAVM)

... ...
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
TMOThermo Fisher Scientific, Inc. -4.95%482.681.0%$793.96m
DHRDanaher Corp. -5.20%221.810.7%$564.07m
ABTAbbott Laboratories -0.41%114.260.8%$537.76m
ISRGIntuitive Surgical, Inc. -1.42%758.732.3%$504.83m
MDTMedtronic Plc -4.52%111.470.6%$426.46m
BSXBoston Scientific Corp. -2.18%35.841.0%$359.73m
DXCMDexCom, Inc. -3.26%349.647.8%$327.01m
BDXBecton, Dickinson & Co. -2.89%250.881.0%$301.73m
SYKStryker Corp. -3.12%230.571.3%$238.49m
QDELQuidel Corp. -0.87%224.217.7%$229.12m
ALGNAlign Technology, Inc. -4.76%509.646.4%$228.49m
EWEdwards Lifesciences Corp. -1.87%84.920.4%$201.32m
PENPenumbra, Inc. 2.03%271.008.3%$197.41m
AAgilent Technologies, Inc. -4.17%118.751.6%$193.08m
BAXBaxter International, Inc. -3.56%77.931.8%$180.96m

Company Profile

PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The firm conducts its operations in four divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy and Emerging Innovations. The GI Health division consists of Edouard Esophageal DNA Test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus Technology. The Minimally Invasive Interventions division consists of CarpX, which is a patented, single-use disposable, minimally invasive device designed to treat carpal tunnel syndrome. The Infusion Therapy division consists of PortIO, which is a novel, patented, implantable, intraosseous vascular medical device; and NextFlo, which is designed to deliver gravity-driven infusions independent of the height of the IV bag. The Emerging Innovations division refers to a diversified and expanding portfolio of innovative products designed to address unmet clinical needs across a broad range of clinical conditions. The company was founded on June 26, 2014 and is headquartered in New York, NY.